Revolution Medicines, Inc.

Revolution Medicines on April 13 presented breakthrough results from a study of a drug against the deadliest type of cancer. Freedom Holding co-founder Igor Klyushnev believes that this story deserves to be directed by a talented director. It is about how breakthrough clinical data is combined with high dynamics of events. And most importantly, it is a story about people who turned out to be ready for important events.

How oncology company Revolution Medicines monetized a year of operations in 48 hours 

Eli Lilly and Company

US pharmaceutical giant Eli Lilly has agreed to buy biotech company Kelonia Therapeutics in a deal worth up to $7 billion, <a href="https://investor.lilly.com/news-releases/news-release-details/lilly-acquire-kelonia-therapeutics-advance-vivo-car-t-cell">according to</a> a press release. Lilly will pay $3.25 billion outright, with the remainder of the amount contingent on the achievement of clinical, regulatory and commercial milestones. The deal is expected to close in the second half of the year.

Eli Lilly to buy oncology drug developer. What is it paying up to $7 billion for?

VolitionRx Limited

Shares of VolitionRx, a micro-cap developer of blood tests for cancer and sepsis, <a href="https://finance.yahoo.com/quote/VNRX/">jumped</a>&nbsp;nearly 26% on Tuesday after the company <a href="https://ir.volition.com/news-events/press-releases/detail/874/volitionrx-highlights-commercial-momentum-and-multi-pillar-execution">reported</a>&nbsp;progress in several research programs and said a newly developed cancer-detection method has attracted interest from potential partners. The company also highlighted breakthrough research on detecting lymphoma in cats. Wall Street analysts <a href="https://www.marketwatch.com/investing/stock/vnrx/analystestimates?mod=mw_quote_tab">say</a>&nbsp;the stock could have nearly 790% upside.

Cancer blood test maker VolitionRX soars 25% in a day on reported commercial progress

Arcellx, Inc.

Gilead Sciences, Inc.

Shares of Arcellx, a mid-cap developer of cell therapies for blood cancers, <a href="https://finance.yahoo.com/quote/ACLX/">surged</a>&nbsp;77% on Monday to a new all-time high after the <a href="https://ir.arcellx.com/news/news-details/2026/Gilead-Sciences-to-Acquire-Arcellx-to-Maximize-Long-term-Potential-of-Anito-cel/default.aspx">announcement</a>&nbsp;that its major partner, Gilead Sciences, will acquire the company at a substantial premium to the market price. For investors, the deal signals that leading pharmaceutical companies increasingly prefer full ownership of late-stage oncology assets, Noble <a href="https://www.channelchek.com/news-channel/gilead-to-acquire-arcellx-in-7-8b-bet-on-next-gen-car-t-leadership">argues</a>.

Cancer drugmaker Arcellx explodes 77% in a day as Gilead will acquire it

Olema Pharmaceuticals, Inc.

Roche Holding AG

Shares of Olema Pharmaceuticals, a small-cap maker of cancer drugs, <a href="https://finance.yahoo.com/quote/OLMA/">soared</a>&nbsp;almost 200% last week, November 18-24. Investors were <a href="https://www.roche.com/media/releases/med-cor-2025-11-18">reacting</a>&nbsp;to positive news on clinical trials from Swiss pharma giant Roche. Olema is advancing a therapy with a similar mechanism of action, meaning Roche’s success has reduced the perceived risks of investing in Olema, Freedom Broker explains. Against this backdrop, at least two Wall Street analysts have <a href="https://finance.yahoo.com/quote/OLMA/">raised</a>&nbsp;their target price on Olema shares.

Oncology drugmaker Olema triples in a week after latest Roche data eases sector risks

Anixa Biosciences, Inc.

The fair value of micro-cap biotech Anixa Biosciences, which is developing, among other projects, a cancer vaccine, is almost three times higher than the current share price, Freedom Broker estimates. The firm has initiated coverage of the stock with a "buy" recommendation. Analysts note that Anixa’s early-stage developments have shown encouraging results and that the company has sufficient cash to finance its programs without diluting shareholders in the near term. The broader biotech sector is also showing signs of sustainable growth.

Freedom Broker initiates on biotech Anixa with 'buy' at TP implying 177% upside

MAIA Biotechnology, Inc.

Shares of micro cap MAIA Biotechnology <a href="https://finance.yahoo.com/quote/MAIA/">jumped</a>&nbsp;almost 9% yesterday, September 11, to end the day at $1.70 per share, an almost two-month high The gain followed the company's&nbsp;<a href="https://ir.maiabiotech.com/news-events/press-releases/detail/150/maia-biotechnology-highlights-positive-efficacy-data-from">announcement</a>&nbsp;that its experimental therapy for lung cancer, which is in the middle of phase II clinical trials, has demonstrated double the efficacy of standard treatment.

MAIA Biotechnology shares jump 9% on upbeat latest lung cancer therapy trial results

Candel Therapeutics, Inc.

Freedom Broker has initiated on Candel Therapeutics, which&nbsp;develops immunotherapies for cancer patients, and estimates the stock has upside of more than 100%. The company has low debt and a large cash pile to finance operations, Freedom Broker points out.

Freedom Broker initiates with 'buy' on cancer therapy developer Candel Therapeutics

Lisata Therapeutics, Inc.

Novo Nordisk A/S

Quotes on Lisata Therapeutics, a pharmaceutical company developing therapies to combat tumors, <a href="https://finance.yahoo.com/quote/LSTA/">gained</a> more than 10% yesterday, April 15, after it announced a partnership with one of the largest industry manufacturers, Catalent, to evaluate the efficacy of a promising Lisata therapy. Since December, Catalent has been owned by Novo Holdings, the controlling shareholder of Denmark’s Novo Nordisk, a global leader in weight-loss medications.

Biotech small cap Lisata Therapeutics jumps 10% on partnership with Novo subsidiary


Quotes on the small-cap MAIA Biotechnology <a href="https://www.marketwatch.com/investing/stock/maia/analystestimates?mod=mw_quote_tab&amp;utm_source=in_materials">jumped</a> almost 6% yesterday, Tuesday, February 4, after the company <a href="https://ir.maiabiotech.com/news-events/press-releases/detail/124/maia-biotechnology-announces-positive-efficacy-updates-for?utm_source=in_materials">revealed</a> phase II clinical trial results for its drug that is said to offer a fundamentally new approach to cancer treatment. The therapy has proved to be superior to existing treatments, MAIA claims, and the chances of U.S. regulatory approval are "stronger than ever." 

Biotech small cap MAIA jumps on positive trial data for its cancer drug

<a href="https://www.who.int/ru/news/item/01-02-2024-global-cancer-burden-growing--amidst-mounting-need-for-services?utm_source=in_materials#:~:text=%D0%B1%D1%8B%D0%BB%20%D1%80%D0%B0%D0%BA%20%D0%BB%D0%B5%D0%B3%D0%BA%D0%B8%D1%85%20(1%2C8,%D1%81%D0%BC%D0%B5%D1%80%D1%82%D0%B8%2C%206%2C8%25).">According</a> to the World Health Organization, one in five people worldwide develops some form of cancer in their lifetime. While certain cancers respond well to treatment, others manage to "shield" themselves from targeted therapies. The micro-cap company MAIA Biotechnology is developing a drug to "trick" cancer cells, infiltrate them, and destroy them from within. As for the investment opportunity, MAIA shares are <a href="https://www.channelchek.com/news-channel/maia-biotechnology-maia-maia-announces-supply-agreement-for-second-phase-2-trial-with-three-new-indications?utm_source=in_materials">valued</a> as having 600% upside by the investment firm Noble Capital Markets.

Outsmarting cancer: Why immune-oncology firm MAIA has 600% upside

Shares of micro-cap company GeoVax, which specializes in cancer treatments and vaccines, rose nearly 7% on Wednesday, January 15. The company announced "significant progress" in early testing of its cancer drug for head and neck cancer and confirmed plans to move to the next phase of clinical trials. Analysts see upside of nearly 550% for GeoVax, which is also developing a monkeypox vaccine.